Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 556.50, up by 7.70 points or 1.40% from its previous closing of Rs. 548.80 on the BSE.

The scrip opened at Rs. 555.00 and has touched a high and low of Rs. 559.00 and Rs. 546.55 respectively. So far 249663 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 608.55 on 12-Feb-2018 and a 52 week low of Rs. 433.15 on 14-Aug-2017.

Last one week high and low of the scrip stood at Rs. 570.70 and Rs. 529.95 respectively. The current market cap of the company is Rs. 131578.96 crore.

The promoters holding in the company stood at 54.38%, while Institutions and Non-Institutions held 32.55% and 13.07% respectively.

Sun Pharmaceutical Industries including its subsidiaries and/or associate companies has received approval from the US Food and Drug Administration (USFDA) for Infugem (gemcitabine in 0.9% sodium chloride injection) 10 mg/mL, for intravenous use in a ready-to-administer (RTA) bag. This is the first USFDA approval for a product from Sun Pharma’s Halol facility post receipt of Establishment Inspection Report (EIR) in June 2018.

Infugem uses a proprietary technology which allows cytotoxic oncology products to be premixed in a sterile environment and supplied to the prescribers in RTA infusion bags.

The addressable market size is approximately $35 million for the 12 months ending March 2018, as per IQVIA.
Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.